{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:51:58Z","timestamp":1792277518376,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T12:20:21Z","timestamp":1666441221000},"page":"e59-e70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cobimetinib Alone and Plus Venetoclax With\/Without Atezolizumab in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-4548","authenticated-orcid":false,"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Dail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Javery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-1769","authenticated-orcid":false,"given":"Grace","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.10.006_bib0001","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.10.006_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.006_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0004","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.006_bib0005","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.006_bib0006","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0007","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.clml.2022.10.006_bib0008","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.10.006_bib0009","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.10.006_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.10.006_bib0011","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.006_bib0012","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-15-1076","article-title":"A phase II trial of AZD6244 (selumetinib, ARRY-142886), an oral MEK1\/2 inhibitor, in relapsed\/refractory multiple myeloma","volume":"22","author":"Holkova","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.10.006_bib0013","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.10.006_bib0014","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood.V126.23.4219.4219","article-title":"Safety and efficacy of venetoclax (ABT-199\/GDC-0199) monotherapy for relapsed\/refractory multiple myeloma: phase 1 preliminary results","volume":"126","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0015","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0016","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J Immunother"},{"key":"10.1016\/j.clml.2022.10.006_bib0017","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.10.006_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.10.006_bib0019","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2022.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.10.006_bib0021","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.clml.2022.10.006_bib0022","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.10.006_bib0023","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/humrep\/dex226","article-title":"Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Mullerian hormone using cluster analysis","volume":"32","author":"Lie Fong","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.clml.2022.10.006_bib0025","doi-asserted-by":"crossref","first-page":"794","DOI":"10.47102\/annals-acadmedsg.V35N11p794","article-title":"A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis","volume":"35","author":"Chan","year":"2006","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.clml.2022.10.006_bib0026","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.10.006_bib0027","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.10.006_bib0028","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.clml.2022.10.006_bib0029","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Supp","key":"10.1016\/j.clml.2022.10.006_bib0031","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-134924","article-title":"Ex vivo drug sensitivity and functional genomics platform identifies novel combinations targeting intrinsic and extrinsic apoptotic signaling pathways in multiple myeloma","volume":"136","author":"Siqueira Silva","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0032","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.10.006_bib0033","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood-2019-123652","article-title":"Dynamics of activated CD8+ T-cells and decreased osteoclasts in the tumor microenvironment are associated with clinical efficacy of Anti-PD-L1 and anti-CD38 combination treatment in relapsed or refractory multiple myeloma","volume":"134","author":"Raval","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.006_bib0034","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/cpt.587","article-title":"Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma","volume":"102","author":"Stroh","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2022.10.006_bib0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cts.13127","article-title":"Evaluation of atezolizumab immunogenicity: clinical pharmacology (part 1)","volume":"15","author":"Wu","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clml.2022.10.006_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cts.13149","article-title":"Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)","volume":"15","author":"Peters","year":"2022","journal-title":"Clin Transl Sci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:55Z","timestamp":1761871255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022017128"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cobimetinib Alone and Plus Venetoclax With\/Without Atezolizumab in Patients With Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}